Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | March 06, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date March 06, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,711.2345 |
Ending reported balance
After 2024-03-06 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2024-03-06 · Exercise / conversion · Acquired 755 · Balance 11,466.2345 Row 2 · 2024-03-06 · Exercise / conversion · Acquired 483 · Balance 11,949.2345 Row 3 · 2024-03-06 · Exercise / conversion · Acquired 2,226 · Balance 14,175.2345 Row 4 · 2024-03-06 · Exercise / conversion · Acquired 4,640 · Balance 18,815.2345 Row 5 · 2024-03-06 · Sale · Disposed 4,134 · Balance 14,681.2345 F1: Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2024-03-06 · Sale · Disposed 3,290 · Balance 11,391.2345 F2: Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2024-03-06 · Sale · Disposed 680 · Balance 10,711.2345 F3: Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $206.94 · Expires 2029-02-13 | Direct | 0 |
Reported balance
After 2024-03-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-06 · Exercise / conversion · Disposed 755 · Balance 0 F4: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $288.78 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2024-03-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-06 · Exercise / conversion · Disposed 2,226 · Balance 0 F6: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $544.08 · Expires 2031-02-13 | Direct | 1,363 |
Reported balance
After 2024-03-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-06 · Exercise / conversion · Disposed 4,640 · Balance 1,363 F7: Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $206.94 · Expires 2029-02-13 | Direct | 0 |
Reported balance
After 2024-03-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-06 · Exercise / conversion · Disposed 483 · Balance 0 F5: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020.
F5: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024.
F6: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021.
F7: Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · derivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,863 Underlying: Common Stock · 126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F6 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 252 | $503.65 | $126,919.80 |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,011.2845 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,263.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,605.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,898.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 127 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,682.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,555.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · balance_after: Adjusted to include 1 additional share of Issuer common stock due to a scrivener's error. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002395 · doc1.xml · derivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 880 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002395 · doc1.xml · derivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,236 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002395 · doc1.xml · derivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,236 Underlying: Common Stock · 6,236 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 14 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109 Underlying: Common Stock · 161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F10 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 13 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270 Underlying: Common Stock · 217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F10 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 12 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,487 Underlying: Common Stock · 127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F10 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 11 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,614 Underlying: Common Stock · 126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F10 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,740 Underlying: Common Stock · 150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F10 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890 Underlying: Common Stock · 816 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F10 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 197 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2032-02-13 F10 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 7,009 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · derivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,009 Underlying: Common Stock · 7,009 shares Expires 2032-02-13 F10 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 235 | $505.53 | $118,799.55 |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,374.2845 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,609.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,448.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 127 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,231.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,104.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004785 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,978.2845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2021. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,595 | $633.00 | $2,908,635.00 |
DisclosureSEC source: 0001567619-21-021392 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,818.2845 F1 · balance_after: Updated to correct a scrivener's error in the Form 4 filed on August 25, 2021, which inadvertently reported the total amount of beneficially owned securities following the reported transaction as 19,494.2845 instead of 19,404.2845. Also includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-016332 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,494.2845 F1 · balance_after: Includes 11.2845 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · derivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,627 Underlying: Common Stock · 10,000 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · price: Not applicable. F10 · derivative.exercise_date: Grant of option to buy 12,627 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2017. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 200 | $565.56 | $113,111.00 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,915 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $565.42 to a high of $565.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 513 | $564.73 | $289,704.28 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,115 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $564.38 to a high of $564.88 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,713 | $564.04 | $966,197.78 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,628 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $563.36 to a high of $564.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,462 | $562.65 | $1,385,252.92 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,341 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $562.26 to a high of $563.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,429 | $561.77 | $802,770.76 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,803 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $561.25 to a high of $562.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,274 | $560.79 | $714,450.66 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,232 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $560.24 to a high of $561.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,370 | $559.77 | $766,878.87 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,506 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $559.23 to a high of $560.22 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,039 | $558.89 | $580,690.24 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,876 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $558.22 to a high of $559.22 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $67.85 | $678,500.00 |
DisclosureSEC source: 0001567619-21-011452 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,476 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-005196 · doc1.xml · derivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,476 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,476 | $67.85 | $100,146.60 |
DisclosureSEC source: 0001567619-21-005196 · doc1.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 15 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,074 Underlying: Common Stock · 217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F11 · price: Not applicable F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 14 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,291 Underlying: Common Stock · 127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F11 · price: Not applicable F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 13 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,418 Underlying: Common Stock · 126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F11 · price: Not applicable F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 12 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,544 Underlying: Common Stock · 150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F11 · price: Not applicable F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 243 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 11 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,694 Underlying: Common Stock · 243 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. F11 · price: Not applicable F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,937 Underlying: Common Stock · 643 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F11 · price: Not applicable F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 183 | Not disclosed Strike: $544.08 | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183 Underlying: Common Stock · 183 shares Expires 2031-02-13 F2 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F11 · price: Not applicable F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,003 | Not disclosed Strike: $544.08 | Not disclosed |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,003 Underlying: Common Stock · 6,003 shares Expires 2031-02-13 F2 · derivative.exercise_price: Closing price of Issuer common stock on the NASDAQ Global Select Market on February 12, 2021. F11 · price: Not applicable F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2022. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 257 | $544.08 | $139,828.56 |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · nonDerivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,427 Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 127 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2021 Filed Feb 18, 2021 00:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-004327 · doc1.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.